Search

Your search keyword '"Sheniqua R Glover"' showing total 2 results
Start Over Author "Sheniqua R Glover" Language english
2 results on '"Sheniqua R Glover"'

1. Novel Vaccine Technologies in Veterinary Medicine: A Herald to Human Medicine Vaccines

Author

Virginia Aida, Vasilis C. Pliasas, Peter J. Neasham, J. Fletcher North, Kirklin L. McWhorter, Sheniqua R. Glover, and Constantinos S. Kyriakis

Subjects
veterinary vaccines, new technology vaccines, food animals, companion animals, infectious diseases, disease control and prevention, Veterinary medicine, SF600-1100
Abstract

The success of inactivated and live-attenuated vaccines has enhanced livestock productivity, promoted food security, and attenuated the morbidity and mortality of several human, animal, and zoonotic diseases. However, these traditional vaccine technologies are not without fault. The efficacy of inactivated vaccines can be suboptimal with particular pathogens and safety concerns arise with live-attenuated vaccines. Additionally, the rate of emerging infectious diseases continues to increase and with that the need to quickly deploy new vaccines. Unfortunately, first generation vaccines are not conducive to such urgencies. Within the last three decades, veterinary medicine has spearheaded the advancement in novel vaccine development to circumvent several of the flaws associated with classical vaccines. These third generation vaccines, including DNA, RNA and recombinant viral-vector vaccines, induce both humoral and cellular immune response, are economically manufactured, safe to use, and can be utilized to differentiate infected from vaccinated animals. The present article offers a review of commercially available novel vaccine technologies currently utilized in companion animal, food animal, and wildlife disease control.

Published
2021
Full Text
View/download PDF

2. Bivalent vaccination with NA1 and NA2 neuraminidase virus-like particles is protective against challenge with H1N1 and H3N2 influenza A viruses in a murine model

Author

Constantinos S. Kyriakis, Vasilis C. Pliasas, Sheniqua R Glover, Zach Menne, Ioanna Skountzou, and Richard W. Compans

Subjects
viruses, Dose-Response Relationship, Immunologic, Neuraminidase, Immunity, Heterologous, complex mixtures, Injections, Intramuscular, Bivalent (genetics), Virus, Article, Mice, Viral Proteins, Influenza A Virus, H1N1 Subtype, Antigen, Orthomyxoviridae Infections, Virology, Animals, Vaccines, Combined, Vaccines, Virus-Like Particle, chemistry.chemical_classification, biology, Influenza A Virus, H3N2 Subtype, Vaccination, virus diseases, Influenza a, Disease Models, Animal, chemistry, Murine model, Influenza Vaccines, Immunoglobulin G, biology.protein, Glycoprotein
Abstract

Neuraminidase (NA) is the second most abundant glycoprotein on the surface of influenza A viruses (IAV). Neuraminidase type 1 (NA1) based virus-like particles (VLPs) have previously been shown to protect against challenge with H1N1 and H3N2 IAV. In this study, we produced neuraminidase type 2 (NA2) VLPs derived from the sequence of the seasonal IAV A/Perth/16/2009. Intramuscular vaccination of mice with NA2 VLPs induced high anti-NA serum IgG levels capable of inhibiting NA activity. NA2 VLP vaccination protected against mortality in a lethal A/Hong Kong/1/1968 (H3N2) virus challenge model, but not against lethal challenge with A/California/04/2009 (H1N1) virus. However, bivalent vaccination with NA1 and NA2 VLPs demonstrated no antigenic competition in anti-NA IgG responses and protected against lethal challenge with H1N1 and H3N2 viruses. Here we demonstrate that vaccination with NA VLPs is protective against influenza challenge and supports focusing on anti-NA responses in the development of future vaccination strategies.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results